DBD vs REGN · P/E 28, rev $3.75B vs P/E 14, rev $14.34B
Diebold Nixdorf, Incorporated (DBD) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Diebold Nixdorf, Incorporated (DBD) is a software - application company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported DBD revenue for 2024-12-31 was $3.75B. Net income was -$14.5M. Revenue was up 130.3% from 2023-12-31 to 2024-12-31. DBD currently screens at market cap $2.82B and trailing P/E 28.1.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
DBD currently screens at market cap $2.82B and trailing P/E 28.1. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the DBD and REGN stock pages for the full models.
Not investment advice.